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Naturally occurring BRCA2 alternate mRNA splicing events in clinically 
relevant samples. 
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Abstract 
 
Background: BRCA1 and BRCA2 are the two principal tumor suppressor genes 
associated with inherited high risk of breast and ovarian cancer.  Genetic testing of 
BRCA1/2 will often reveal one or more sequence variants of uncertain clinical 
significance (VUS), some of which may affect normal splicing patterns and thereby 
disrupt gene function.  mRNA analyses are therefore among the tests used to 
interpret the clinical significance of some genetic variants.  However, these could be 
confounded by the appearance of naturally occurring alternative transcripts 
unrelated to germline sequence variation or defects in gene function.  To 
understand which novel splicing events are associated with splicing mutations and 
which are part of the normal BRCA2 splicing repertoire, a study was undertaken by 
members of the Evidence-based Network for the Interpretation of Germline Mutant 
Alleles (ENIGMA) consortium to characterize the spectrum of naturally occurring 
BRCA2 mRNA alternate splicing events.  Methods: mRNA was prepared from 
several blood and breast tissue-derived cells and cell lines by contributing ENIGMA 
laboratories.  cDNA representing BRCA2 alternate splice sites was amplified and 
visualized using capillary or agarose gel electrophoresis, followed by sequencing. 
Results: We demonstrate the existence of 24 different BRCA2 mRNA alternate 
splicing events in lymphoblastoid cell lines and both breast cancer and non-
cancerous breast cell lines.  Conclusions: These naturally occurring alternate 
splicing events contribute to the array of cDNA fragments that may be seen in assays 
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for mutation-associated splicing defects.  Caution must be observed in assigning 
alternate splicing events to potential splicing mutations.  
 
 
Introduction 
 
Breast cancer is among the leading causes of cancer deaths in women 
worldwide (http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx).  While the 
majority of breast cancers are sporadic, some are associated with inherited 
“mutations” (pathogenic variants) in the BRCA1 (MIM 113705) or BRCA2 
(MIM600185) tumor suppressor genes.  Indeed, BRCA1/2 pathogenic variants are 
the strongest genetic predictors of familial breast/ovarian cancer syndrome.  
Accordingly, individuals with strong family histories of breast and/or ovarian 
cancer are advised to seek genetic testing for BRCA1/2 sequence variants, results of 
which can be used to inform disease screening, disease prevention, and disease 
treatment options.   
 
BRCA1/2 clinical testing typically involves sequence analysis of all coding 
exons and adjacent intronic sequences.  Though there are several known pathogenic 
missense alterations for each gene, most pathogenic variants are “protein 
truncating,” and include frame-shifting insertion/deletions, nonsense substitutions, 
and base substitutions that alter normal physiological splicing.  An ongoing 
challenge in clinical genetic testing is characterization of DNA sequence variants of 
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 5 
uncertain clinical significance (VUS) [1 2].  Effective genetic counseling requires that 
the pathogenicity of these variants be determined [3].   
 
To address this problem, the Evidence-based Network for the Interpretation 
of Germline Mutant Alleles (ENIGMA) is exploring a series of approaches to 
characterize the potential pathogenicity of BRCA1/2 VUS identified during clinical 
screening, including those that may affect splicing [2 4 5].  These investigations can 
be complicated by the observation that both BRCA1 and BRCA2 genes are 
transcribed into multiple naturally occurring mRNA splice isoforms independent of 
any genetic variants, and that these isoforms can vary in expression level between 
different individuals.  Thus, presumed aberrant transcript patterns seen in the 
presence of a VUS, in some cases, could be unrelated to the VUS and thus not 
necessarily pathogenic.   
 
In order to accurately interpret clinical splicing assays, it is necessary to 
provide an overview of the naturally occurring alternate splicing events. ENIGMA 
collaborators have recently demonstrated the value of comprehensive approaches 
to catalogue previously unrecognized naturally occurring BRCA1 mRNA transcripts 
[6].  Here, we report a complementary study conducted to provide the first 
systematic catalog of human alternate BRCA2 mRNA splicing events.  We have 
performed experiments in different blood-related RNA sources (from both healthy 
controls and breast cancer patients with or without known BRCA1/2 pathogenic 
variants), breast cancer cell lines, and non-breast cancer cell lines to show that the 
Page 15 of 62
https://mc.manuscriptcentral.com/jmedgenet
Journal of Medical Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 6 
isoforms overlap in their expression profile across clinically relevant sources of 
mRNA.  
 
Materials and Methods 
 
Phase Ia: BRCA2 alternate splicing events reported by participating ENIGMA 
laboratories:  
Nine contributing ENIGMA laboratories used various cDNA  amplification 
strategies to identify naturally occurring alternate splicing events in controls who 
do not have breast cancer, from whole blood leukocytes (LEUs), ficoll-isolated 
peripheral blood mononuclear cells (PBMCs), primary cultures of stimulated 
peripheral blood lymphocytes (PBLs) and lymphoblastoid cell lines (LCLs), and one 
healthy breast tissue (BREAST) (Fig. 1, Table 1, and Table S1).  Phase Ia was a 
collection of independent observations by individual ENIGMA participating groups, 
each using samples and methodologies available to those particular laboratories 
prior to the coordinated effort.  The contributions of each group are described in 
Table S1.  Briefly, cDNAs were generated with BRCA2 cDNA-specific primers or 
random hexamers/oligo dT, and these were amplified by PCR with BRCA2-specific 
primers designed at each contributing laboratory (all sequences are available upon 
request).  Products were visualized on agarose gels or with capillary 
electrophoresis.  In most cases splicing isoforms were verified by sequence analysis 
at the originating institution. Samples and methods have been described in detail 
elsewhere [6].  Details are presented in the Results section.  In brief, 22 BRCA2 
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 7 
alternative splicing events were identified.  Phase Ia was conducted to detect BRCA2 
splicing events, not to address quantitative aspects. Yet visual inspection of capillary 
electrophoresis experiments allowed us to annotate four splicing events (∆3, ∆6q,7, 
∆12, and ∆17,18) as predominant, a qualitative annotation indicating that they 
represent a non-negligible/substantial fraction of the total alternate splicing events, 
in particular if compared with other (minor) events   (see representative examples 
in Fig.2).  Predominant events are associated with much higher detection rates than 
minor events, regardless of the samples analyzed (Table 1). 
 
Twenty-two candidate isoforms reported by ENIGMA collaborators were 
compiled and submitted to the University of Chicago where their expression in LCLs 
and breast normal and tumour cells was tested by isoform-specific RT-PCR and 
sequencing analyses as described below.  Two additional potential alternate splicing 
events not seen in phase Ia were also tested: ∆9-11, which was reported in the 
ENCODE RNA-Seq dataset from the California Institute of Technology 
http://www.ncbi.nlm.nih.gov/geo/info/ENCODE.html, and ▼5p, which was 
predicted from a spliceogenic variant reported in a previous study [5]. 
 
 
Phase Ib: Alternate splice product detection and sequencing:  
An exon-scanning strategy was developed at the University of Chicago to 
identify potential abundant BRCA2 splicing isoforms.  This strategy was designed 
independently of the design or results in Phase Ia.  Briefly, eighteen primer pairs 
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were designed to amplify portions of the BRCA2 cDNA flanking exons 2 (alone), 3 
(alone), 4 through 6, 5 and 6, 5 through 7, 9 alone, 12 and 13, 13 alone, 14 and 15, 
15 alone, 16 alone, 16 and 17, 18 through 20, 19 and 20, 19 through 22, 23 and 24, 
23 through 25, and 23 through 26.  These primers are able to generate both full-
length RT-PCR products and any product resulting from intervening exon-skipping 
or alternate splice-site choice.  RT-PCR products were run on 1% agarose gels and 
visualized with ethidium bromide staining and UV transillumination according to 
standard protocols (Fig. 3A).  Gel isolated cDNA fragments were sequenced using 
the forward or reverse RT-PCR primer using standard protocols.  The exon-scanning 
strategy was performed on mRNA prepared from MCF7, MCF10A, and 184A1 cell 
lines.   This strategy covered all cDNA fragments except those containing exons 10 
(1,116 bp) or 11 (4,932 bp) because their large sizes did not permit convenient 
analysis of full-length large-exon cDNA fragments. 
 
Phase II: Isoform-specific RT-PCR primer design:  
To validate potentially low-abundance BRCA2 alternate splicing events with 
utmost specificity, we designed exon boundary junction-spanning isoform-specific 
RT-PCR primers.   We used these to verify specific candidate splicing isoforms 
detected in phase I without competition from full-length splicing products [7-9].  
These isoform-specific primers contained three to five bases of 3’ sequence 
designed to hybridize with the 5’ end of the adjacent exon in either the full length 
BRCA2 mRNA or in an isoform resulting from exon skipping (Fig. 4, Table S2).  As we 
use a one-step RT-PCR method (see below), the reverse PCR primer is also the 
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 9 
primer used by the reverse transcriptase to generate the single-stranded cDNA.  In 
our experiments, when the reverse primer is the isoform-specific primer, it often 
amplifies both full-length and alternate splicing events, possibly because nuclease 
activity trims back the isoform-specific 3’ end of the primer, or because of some kind 
of non-specific binding event.   However, this occurs less frequently when the 
isoform-specific primer is the forward RT-PCR primer.  We have therefore designed 
all isoform-specific RT-PCR primers as forward primers (Table S2).    
  
 
Patient samples and cell lines:  
 A description of the patient samples and cell lines used in phase II is 
provided in the Supplementary Materials and Methods. 
 
RT-PCR:  
mRNA was prepared from cells using RNeasy Mini Kit  (QIAGEN) according 
to the manufacturer’s protocol.  In contrast to other studies of alternate splicing 
events, no inhibitors of nonsense-mediated mRNA decay (NMD) were used in Phase 
II.  RT-PCR was performed using the SuperScript III One-Step RT-PCR System with 
Platinum Taq DNA Polymerase (Life Technologies) according to the manufacturer’s 
protocol.  PCR conditions were empirically optimized for each primer pair using a 
standard set of mRNAs (10-50 ng per reaction) prepared from select LCLs and 
breast cell lines.     
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Results  
 
BRCA2 alternate splicing isoforms reported by participating ENIGMA laboratories 
(Phase Ia):  
Nine groups contributed reports totaling 22 unique alternate BRCA2 splicing 
events detected by RT-PCR in mRNA samples prepared from various cell types (Fig 
1 and Table 1).  All splicing events were supported by direct sequencing evidence, 
with the only exceptions of ∆5,6; ∆6; ∆12,13; and ∆23p, that were predicted from 
capillary EP size-calling.  All events were detected by capillary EP, but only 8 events 
(36%) were detectable by conventional agarose gel electrophoresis/EtBR staining.  
We were able to detect up to 15 events (68%) in LEU samples, 17(77%) in PBMCs 
samples, 18 (82%) in PBL samples, and 22 (100%) in LCL samples. We tested 21 
splicing variants in RNA extracted from one healthy breast tissue (BREAST), 
detecting 10 (48%).  The low value is likely related to the fact that each alternate 
splicing event was tested only once due to the scarcity of biological material (see 
Table 1 for further details).   
 
Exon Scanning (Phase Ib):  
Only three isoforms (∆3, ∆6q7, and ∆12) were detected unambiguously by 
exon scanning RT-PCR followed by conventional EtBr-stained gel electrophoresis (a 
low sensitivity detection method). The data nonetheless confirms ∆3, ∆6q7, and ∆12 
as major alternative splicing events. 
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Specificity of isoform-specific RT-PCR primers:   
To validate and survey all 22 alternate splicing events reported in phase I, an 
isoform-specific RT-PCR strategy was devised to amplify corresponding alternate 
cDNAs (see below).  Specificity for individual alternate splicing event products is 
determined by several bases at the 3’ ends of forward PCR primers that span 
splicing junctions being investigated. One potential source of non-specific cDNA 
amplification by this method is the possibility of a “loop-out” structure formation by 
the exon junction-spanning isoform-specific primer that could result in an exon-
skipping artifact (Fig.S1).  This is unlikely to be a major contributor to the detection 
of isoforms using isoform-specific RT-PCR used in this study because of two sets of 
observations.  First, most alternate splicing events were not detected in every 
experiment, thus providing negative internal controls for most potential loop-out 
products.  Specifically, of the 24 isoform-specific primers designed to identify exon-
skipping isoforms, only one (BRCA2 ex 2-4 F, designed to identify the BRCA2 ∆3 
isoform) amplified a product in every cell type examined.  In our experiments, 
BRCA2 ∆3 is easily detected with conventional flanking RT-PCR primers not subject 
to loop-out artifact conditions.  All other isoform-specific primers designed to 
identify exon-skipping isoforms failed to detect the target isoform in at least one cell 
line, whereas all corresponding control primers (i.e., those designed amplify to full-
length BRCA2 cDNA) amplified the correct RT-PCR product in all cell lines.  Thus, for 
these primers, starting conditions for RT-PCR were not sufficient to generate exon-
skipping isoforms by looping out or other false priming events.  Indeed, a loop-out 
structure is predicted to be energetically unfavorable given the very short exon-
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spanning 3’ sequence of the isoform-specific primer.  Second, we tested the ability of 
several isoform-specific RT-PCR primers to generate forced loop-out RT-PCR 
products.  This was done by using exon-skipping isoform-specific RT-PCR primers in 
PCRs with gel-isolated full-length cDNA products as templates.  Under these 
conditions, exon-skipping cDNAs could only be generated by spanning and 
amplifying a loop-out intermediate.  We tested twelve isoform-specific forward RT-
PCR primers representing exon-skipping isoforms for their ability to generate a 
forced loop-out product against a full-length template (Fig. S1).  Six of the twelve 
were unable to force the generation of exon-skipping products from the full-length 
template.  The other six were able to generate exon-skipping products when 
provided with large amounts of starting template.  The primer that could generate a 
forced loop-out amplification with the smallest amount of input template was 
BRCA2 ex 11-14 F (designed to amplify the BRCA2 ∆12,13 splicing isoform).  This 
primer was able to amplify a BRCA2 ∆12,13 product from 0.01 ng of full length cDNA 
template, but not from 5 X 10-5 ng of cDNA, an amount over a hundred fold in excess 
of the corresponding  full-length cDNA in the first round of an RT-PCR reaction using 
our conditions, assuming 100 ng RNA contains roughly 7 X 104 copies of a typical 
rare message [10].  We therefore conclude that exon-skipping cDNA isoforms are 
unlikely to be artificially generated by isoform-specific primers under our RT-PCR 
conditions. 
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Isoform-specific RT-PCR amplification and sequence analysis (Phase II):  
The naturally occurring BRCA2 splicing isoforms reported by contributing 
institutions were collected as described in Materials and Methods for Phase Ia 
(Table 1).  These were then validated at the University of Chicago using isoform-
specific RT-PCR in MCF7, HCC1937, BT20, MCF10A, 184A1, 184B5, and at least ten 
lymphoblastoid cell lines.  Breast cell lines were included to address whether major 
differences in splicing events exist between clinically accessible blood-derived cells 
and cells derived from tissue affected by BRCA2-associated disease; all 24 alternate 
splicing events assayed were detected in the examined cell lines with variable 
frequencies, ranging from 29% (∆9-11) to 100% (∆3) positive samples (Table 2) 
and validated by sequence analysis.  Representative cDNA fragments identified by 
scanning RT-PCR are shown in Fig 3B and an example of an isoform confirmed by 
isoform-specific RT-PCR is shown in Fig 4B.  Only 7/24 (29%) of the naturally 
occurring splicing events (namely, BRCA2 exon-skipping alternate splicing events 
∆3; ∆5; ∆6; ∆5,6; ∆12; ∆17,18; and ∆18) were reported previously in the literature 
(Table 2).  These were described as low-level background exon-skipping events in 
negative control samples used to characterize exon-skipping events associated with 
pathogenic sequence variants [11-17]. 
 
Of the 24 isoforms confirmed by isoform-specific RT-PCR, there are five (▼
5p, ∆6q7, ▼20A, ∆22-23p, and ∆23p) that are not simple exon-skipping isoforms 
(Fig 5).  ▼5p represents an alternate splice acceptor site and includes 23 bases of 
intron 4 appended to the 5’ end of exon 5.   ∆6q7 lacks exon 6 almost completely, 
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except for two nucleotides (TG), and lacks exon 7 completely.   ▼20A represents a 
cryptic exon, in which a 64 base sequence from intron 20 is inserted between exons 
20 and 21.  ∆23p and ∆22,23p also represent an alternate splice site acceptor.  In 
this case however, the acceptor lies within exon 23, truncating it by 51 bases on the 
5’ end.  
 
The ▼5p finding was assayed on the presumption that it was a possible 
splicing event. In an unrelated study [5] an isoform containing 18 intronic 
nucleotides upstream exon 5 was reported in a subject carrying a c.426-12_c.426-
8delGTTTT that results in the use of a cryptic acceptor site.  The corresponding 
isoform, using the same acceptor site in a wild type allele, would be the ▼5p 
alternate splicing event described here. Although the ▼5p splicing event was not 
observed previously in RNA samples from LCLs of BRCA1/2 pathogenic variant 
carriers or controls [5], or by contributing members for Phase Ia of this study, the 
isoform-specific RT-PCR analysis revealed this splicing event in 5/10 LCLs, BT20, 
MCF10A, and 184A1 (Table 2).   
 
Another splicing event, ∆9-11, was not tested by contributing laboratories 
during phase I but was assayed because it appeared in the ENCODE RNASeq data.  
This splicing event was identified by isoform-specific RT-PCR in 2/11 LCLs as well 
as BT20 and 184A1.   
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Several BRCA2 cDNA fragments representing alternate splicing events were 
detectable in most cell lines examined, though not all appeared in every cell type 
tested.  For example, ∆3-7, ∆6q7, and ▼20A were all detectable as Phase II agarose 
gel bands from isoform-specific RT-PCR in all the breast cell lines tested and the 
majority, but not all of LCLs.  In contrast, ∆9-11 was seen in only 2/6 breast cell lines 
and only 2/11 LCLs, while ∆20 was observed in only one breast cell line (184A1), 
even though it was detected in the majority of LCLs tested (Table 2).  Similarly, some 
cell lines produced detectable levels of most BRCA2 alternate splicing event cDNA 
fragments, while others did not.  For example, in this survey, all alternate splicing 
events except ∆4 were detected in 184A1, while only 11/24 mRNA splicing isoforms 
were detected in 184B5, a cell line derived from the same individual as 184A1.  
These cell types are karyotypically and genetically similar, but not identical.  Both 
are p16 negative, wild type for RB1, and originally wild type for TP53 though some 
184A1 lineages have developed deficiencies in p53 functions [18].  It is not clear 
whether different synthesis and degradation rates of isoforms resulting from 
alternate splicing events are inherent to these cell lines or are influenced by subtle 
differences in cell growth and RNA preparation and storage conditions.  However, it 
is important to note that the expression of many alternate splicing events can be 
highly variable within and between cell types, which is an important consideration 
when interpreting splicing assay results in connection with potential molecular 
effects of a VUS.  Collectively, these observations are consistent with the view that 
many alternate splicing isoforms may be sensitive to cell growth conditions and 
RNA preparation and storage conditions such that expression patterns may show 
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variable levels between experiments.  It is also possible that some cDNAs are subject 
to stochastic PCR amplification, as we have demonstrated previously for BRCA1 
splicing events [6].  
 
Discussion: 
Clinical sequencing of BRCA1 and BRCA2 is recommended to anyone with a 
strong family or personal history of breast/ovarian cancer.   To provide the most 
complete information for genetic counseling, it is essential to describe the likely 
clinical significance of VUS identified during screening.  RT-PCR analysis of any 
variant that could affect splicing is a powerful and efficient tool for identifying high 
frequency exon skipping or intron retention events in mRNA that is easily prepared 
from peripheral blood or derivatives thereof.  Cases where complete exon skipping 
from the mutant allele typically correspond to pathogenicity.  However, it is not yet 
possible to know how much reduction of normal message accumulation constitutes 
pathogenicity, nor do we know whether any alternate splice variants might result in 
dominant negative effects on normal gene activity.  Addressing these questions will 
require further research. . 
  
 The purpose of this study is to address a previously underappreciated 
challenge to interpreting splicing assays: the frequent occurrence of naturally 
occurring mRNA transcripts that can be mistaken for variant-associated splicing 
defects. In some cases, a potential spliceogenic variant might have modest effects on 
splicing and merely increase the frequency of a naturally occurring alternate mRNA 
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splicing event, maintaining the expression of full-length mRNA.   In such cases the 
remaining full-length mRNA could provide some BRCA2 function.  This result is 
especially important as numerous BRCA2 splicing “mutations” have been reported, 
supported at least in part by the appearance of “novel” RT-PCR products reported 
here as potential background isoforms.  As shown in Table 3, 17/24 naturally 
occurring splicing isoforms reported in this study have been previously reported to 
be aberrant transcripts associated with “mutations” as determined by various 
assays (see references in Table 3).  In addition, the analysis must capture properly the 
alternative splicing existing in the region of interest to avoid misinterpretations, as 
illustrated previously for BRCA1 alterations in exon 9 and BRCA1 splicing isoform Δ
9,10  [19]. For instance, it is not obvious whether the main outcome of impairing BRCA2 
exon 17 splicing sites should be exon 17 skipping, or exon17,18 skipping (since, like 
BRCA1 Δ9,10,  BRCA2 Δ17,18 is already a predominant event in control samples). In 
this regard, the effect of the BRCA2 c.7806-9T>G (IVS16-9T>G) variant on splicing has 
been analyzed by RT-PCR with a forward primer positioned in exons 15 and a reverse 
primer positioned in exon 18 [20], therefore, excluding from analysis Δ17,18 transcripts. 
In our opinion, an analysis with a reverse primer located in exon 19 would be more 
informative.  
 
Indeed, all BRCA2 exons except 4, 10, 11, 12, and 20 have been reported to be 
associated with at least one pathogenic variant near the intron/exon boundary, and 
designated as pathogenic due to assumed/known splicing defects by the Breast 
Cancer Information Core (BIC) (http://research.nhgri.nih.gov/bic).  When applying 
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splicing assays using RT-PCR to identify aberrant splicing products associated with 
DNA sequence variants near intron/exon boundaries, it is important to remember 
that such splicing events exist as part of the natural splicing process regardless of 
the presence of spliceogenic variants, and that varying amounts of full-length mRNA 
may be produced from the same allele.  
 
In humans, the average number of protein coding transcripts per locus is 
roughly four, according to the latest GENCODE release (version 24, 
http://www.gencodegenes.org/stats/current.html). Loci with more than 20 
annotated splicing isoforms are very rare [21]   Our data (up to 24 splicing events, 
including 4 predominant) suggests that BRCA2 is probably in the upper limit of an 
average locus for the number of alternate splicing events.  Yet, this is in contrast 
with BRCA1, a genomic locus similar to BRCA2 in size ( ≈81Kb vs. ≈84Kb) and 
number of exons (23 vs. 27), but with a notable  higher level of alternative splicing 
(up to 63 splicing events, including 10 predominant), according to a recent study 
conducted by the ENIGMA consortium with a very similar methodology [6]. This 
difference may reflect the well establish link between protein disorder (a structural 
feature of BRCA1 but not BRCA2 proteins) and high levels of alternative splicing [22 
23]..   
 
In summary, we have presented an overview of 24 alternate splicing events 
associated with normal BRCA2 mRNA processing.  These results are of importance 
to the design and interpretation of mRNA splicing assays, construct-based or of 
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patient material, that are commonly used to assess whether VUS lead to aberrations 
that are phenotypically equivalent to a molecular null (ie a gene deletion).  Recent 
studies have shown that detection of alternate splice events can be highly variable 
between laboratories and is quite sensitive to variations in cell types, cell growth 
conditions, mRNA preparation, and RT-PCR methodology [5 6 24].  
Recommendations have been made to help make methodologies and reporting of 
alternate splicing isoforms more uniform, including inhibition of NMD, sequence 
confirmation, proper primer design, presentation of data from at least ten control 
samples of the same cell type to reveal potentially rare alternate splice isoforms, 
quantifying the variant allele contribution to full-length mRNA isoforms, and 
quantifying the level of “aberrant” transcripts relative to the full-length transcript 
[24].  These, however, are suggestions for achieving uniformity of alternate splicing 
event detection and quantification, but not directly characterizing the risk 
phenotype associated with a genetic variant in families.  Moreover, disease-
associated alternate-splicing events would likely be associated with loss of 
heterozygosity (LOH) in the affected tissues.  Thus, examination of relative levels of 
“normal” and “aberrant” transcript levels in blood-derived may not reveal levels of 
exclusively “aberrant” transcript levels in affected tissues.  Where interpretation of a 
splicing aberration is not straight-forward, the full phenotypic consequence of 
variants should preferably be assessed with additional evidence from multifactorial 
models that incorporate largely evidence based on the clinical characteristics of 
carriers of bona fide pathogenic variants [25 26].   
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Note: After the completion of this work, several contributing labs on this study 
reported identification of BRCA2 cDNA fragments with combined alternate splicing 
events, ▼20A,∆22, and ▼20A, ∆22,23.  Others identified BRCA2 ∆11, BRCA2 ∆11-
12, and ∆11-13 in wild type controls while investigating the splicing effects of the 
IVS11+1G>C spliceogenic variant (Table 2).  We anticipate other alternate splicing 
events and combinations will be identified over time and require characterization.    
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Figure and Table Legends 
 
Fig. 1.  Schematic diagram showing the process of identification and validation of 
alternate splicing events of BRCA2 mRNA.  Alternate splicing events submitted by 
contributing ENIGMA members were identified in healthy controls from whole 
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blood leukocytes (LEUs), peripheral blood mononuclear cells (PBMCs), primary 
cultures of stimulated blood lymphocytes (PBLs), and lymphoblastoid cell lines 
(LCLs) (Phase Ia).  cDNA exon scanning was performed using mRNA prepared from 
MCF7, MCF10A, and 184A1 (Phase Ib).  The two alternate splicing events added 
between Phases I and II are predicted events ▼5p (from a previous study) and ∆9-
11, reported in ENCODE (see text). 
 
Fig.2. Representative examples ofagarose and capillary electrophoresis analyses 
performed in Phase Ia. BRCA2 alternative spliced events were detected by RT-PCR 
with forward and reverse primers located in the indicated exons. Size differences 
between full-length and alternative splicing transcripts are indicated in nucleotides 
(nt). We indicate both the difference as determined by capillary electrophoresis 
analyses (size-calling performed with GeneScan software), and (in brackets) the 
expected difference based on BRCA2 exons size.  Note the qualitative differences (in 
terms of relative signal compared with the full-length) between predominant (∆3, 
∆6q,7, ∆12, ∆17,18) an minor (∆2 ∆5, ∆5_7, and ∆12,13) events .Predominant events 
were consistently detected in EtBr-stained agarose gels. Note that BRCA2 ∆12 is 
analyzed with different RT-PCR reverse primers in capillary (left) and agarose 
(right) electrophoresis.  
 
Fig 3. BRCA2 alternate splice products detected by scanning RT-PCR (Phase Ib).  A. 
Primers flanking one or more exons were designed to detect alternate splice 
products.  The colored horizontal bars represent any region of a BRCA2 mRNA 
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molecule with any three exons (arbitrarily colored red, blue, and green).  Colored 
arrows represent RT-PCR and cDNA PCR primers.  The top figure represents a full 
length mRNA molecule according to the reference sequence (NCBI Accession 
Number NM_000059), and the bottom figure represents a fragment of a 
corresponding BRCA2 mRNA that has undergone an alternate splicing event (in this 
case, exon skipping).  Examples of alternate splicing event detection are shown for 
∆3 (B) and ∆12 (C).  Full-length RT-PCR products (upper bands) and exon-deleted 
isoforms (lower bands) are shown next to electropherograms demonstrating the 
corresponding exon-exon junctions.  The highest molecular weight band in B and C 
likely represents a heteroduplex containing some strands of ∆3 and ∆12 and full-
length RT-PCR products, respectively. 
 
Fig 4.  BRCA2 alternate splice products are amplified by isoform-specific RT-PCR.  A. 
Illustration of isoform-specific RT-PCR primer design, with an upstream primer 
specific for a portion of a full length cDNA including red, blue, and green exons (top) 
or specific for an exon-skipping cDNA that lacks the blue exon (bottom).  Note the 
forward primer with the green sequence 3’ end is unable to amplify the full-length 
cDNA fragment and the forward primer with the blue 3’ sequence end is unable to 
amplify the exon-skipping product.  An example of isoform-specific RT-PCR is 
shown.  B.  An agarose gel shows RT-PCR products generated using primers for the 
exon 18-19 junction (lane 1) or the exon 18-20 junction unique to the ∆19 isoform 
(lane 2).  C.  Corresponding electropherograms confirming the identities of the RT-
PCR products.   
Page 35 of 62
https://mc.manuscriptcentral.com/jmedgenet
Journal of Medical Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 26
 
Fig 5.  Structures of five BRCA2 alternate splice products including cryptic splice 
donor/acceptor sites.  A. ∆6q7, which contains an exon 6-derived TG dinucleotide 
between flanking exons 5 and 8.  B. ▼5p, which results from a cryptic intronic splice 
acceptor site 23 bases from the 5’ end of exon 5.  C. ▼20A results from a cryptic 
exon within IVS 20.  D. ∆23p and ∆22,23p both use a cryptic splice acceptor site 
within exon 23.  
 
Fig. S1.  Control for hypothetical “loop-out” artifact.  A. Model of exon-skipping 
isoform-specific RT-PCR showing non-amplification (note the green sequence 3’ 
end) (top), isoform-specific RT-PCR (middle), and a hypothetical “loop-out” product 
amplification (bottom).  B. Isoform specific PCR primers in amplification reactions 
with gel purified full-length cDNA fragments.  (Left) a BRCA2 cDNA fragment 
containing exons 3 through 8 amplified with primers specific for the exon 3-4 
junction or the exon 3-8 junction formed in the ∆4-7 mRNA isoform. Note the small 
amount of full-length cDNA amplified by the primer specific for the exon-skipping 
isoform.  This may be due to nuclease activity removing the 3’ terminal isoform-
specific bases from the amplification primer or possibly non-specific priming.  
(Middle) a cDNA fragment containing exons 19 through 21 amplified with primers 
specific for the exon 19-20 junction or the 19-21 junction formed in the ∆20 mRNA 
isoform.  (Right) a cDNA fragment containing exons 17 through 19 amplified with 
primers specific for the exon 17-18 junction or the 17-19 junction formed in the ∆18 
isoform.  Note some amplification of both full-length and ∆18 cDNA, possibly from a 
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loop-out artifact that might occur when PCR conditions include very large amounts 
of template.  C. water control. 
 
Table 1.  BRCA2 alternate mRNA splicing events identified in Phase Ia.  mRNA 
positions (HGVS nomenclature), coverage (the number of times an alternate splicing 
event was assessed, including multiple assessments of the same sample), detection 
rates (number of positives divided by the coverage), and methods are indicated. seq, 
direct sequencing.  QA, qualitative abundance. LEU, whole blood leukocytes. PBMC, 
peripheral blood mononuclear cells.  . PBL, peripheral blood lymphocytes.  LCL, 
lymphoblastoid cell lines.  BREAST, breast tissue.  Predominant alternate splicing 
events are indicated in bold.  Gray boxes indicate a positive detection for alternate 
splicing event. 
 
 
Table 2.  BRCA2 alternate mRNA splicing events detected during Phase II.  Alternate 
splicing events, also indicated by their mRNA position, were detected in a subset of 
lymphoblastoid cell lines (LCLs) or breast cell lines as indicated.  FS, frameshift; 
PTC-NMD, premature termination codon followed by a predicted nonsense-
mediated mRNA decay.  CDS, coding sequence (predicted amino acids of the portion 
of the protein removed by the deletion).  The references for those previously 
reported in the literature are Bieche et al. (1999) [11], Claes et al. (2003) [12], 
Farrugia et al. (2008) [13], Hansen et al. (2010) [14], Santarosa et al. (1999) [15], 
Walker et al. (2010) [16], and Houdayer et al. (2012) [17]. 
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Table 3.  BRCA2 alternate mRNA splicing events have been detected in association 
with mutations that affect normal splicing patterns as indicated [4 12-17 20 27-48]. 
 
Table S1.  Nine different groups tested samples from eight different laboratories for 
the indicated alternate splicing events.  For each group, the number of alternate 
splicing events detected/the number of cell lines tested is indicated.  LEU, whole 
blood leukocytes. PBMC, peripheral blood mononuclear cells.  PBL, peripheral blood 
lymphocytes.  LCL, lymphoblastoid cell lines.  BREAST, breast tissue.  Participating 
groups: INT, Milano (Istituto Nazionale dei Tumori (INT), Milano); HVH, Barcelone  
(University Hospital Vall d’Hebron, Barcelona); HCSC, Madrid (Hospital Clínico San 
Carlos, Madrid); MU, Maastrich (Maastricht University, Maastricht); QIMR, Brisbane 
(QIMR Berghofer Medical Research Institute, Brisbane); Cologne University; 
Southampton General Hospital; USC, Santiago de Compostela (Grupo de Medicina 
Xenómica-USC, CIBERER, IDIS, Santiago de Compostela).  In addition to these seven, 
two other groups reported sequence identification of some alternate splicing events 
without reporting frequencies.  These were the IDIBELL–Catalan Institute of 
Oncology, Barcelona, and a group of ten French labs led by Claude Houdayer 
(Institut Curie and Université Paris Descartes).   
 
Table S2.  RT-PCR primers used to detect full-length BRCA2 mRNA fragments or 
fragments resulting from alternate splicing events.  Forward primers specific for 
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full-length fragments have blue sequence at their 3’ ends, and corresponding 
forward primers specific for alternate splicing events terminate with green 
sequence.  Both full length and alternate splicing event RT-PCRs use the same 
reverse primer. 
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Table 1 
  Phase Ia         
Alternate 
BRCA2 
splice event 
mRNA position coverage 
detection 
rate 
Evidence QA LEUs PBMCs PBLs LCLs BREAST 
∆2 r.38_67del106 61 28% seq Minor 0/13 0/8 11/19 6/20 0/1 
∆3 r.68_316del249 102 97% seq Predominant 34/34 16/16 17/19 31/32 1/1 
∆3,4 r.68_425del359 85 51% seq Minor 13/31 8/16 7/17 15/20 0/1 
∆3−7 r.68_631del564 30 70% seq Minor not tested 5/8 2/7 12/15 not tested 
∆4 r.317_425del109 91 16% seq Minor 0/31 3/16 2/17 10/26 0/1 
∆4−7 r.317_631del315 52 63% seq Minor 5/20 7/8 6/7 15/16 0/1 
∆5 r.426_475del50 89 24% seq Minor 2/39 4/16 4/7 10/26 1/1 
∆5,6 r.426_516del91 97 3% inferred Minor 2/32 0/16 0/7 1/41 0/1 
∆5−7 r.426_631del206 104 31% seq Minor 3/39 8/16 5/7 15/41 1/1 
∆6 r.476_516del41 104 17% inferred Minor 17/39 0/16 0/7 0/41 1/1 
∆6q,7 r.478_631del154 108 100% seq Predominant 39/39 16/16 11/11 41/41 1/1 
∆12 r.6842_6937del96 36 83% seq Predominant 8/13 5/8 10/10 6/6 1/1 
∆12,13 r.6842_7007del166 33 3% inferred Minor 1/13 0/8 0/7 0/4 0/1 
∆17 r.7806_7976del171 95 8% seq Minor 034 0/16 0/24 7/20 1/1 
∆17,18 r.7806_8331del526 125 100% seq Predominant 44/44 16/16 26/26 38/38 1/1 
∆18 r.7977_8331del355 124 99% seq Minor 43/43 16/16 25/26 38/38 1/1 
∆19 r.8332_8487del156 101 34% seq Minor 1/34 5/16 9/22 18/29 not tested 
∆20 r.8488_8632del145 79 20% seq Minor 2/19 2/16 3/20 8/23 1/1 
▼20A r.8632-r.8633ins8633-1327_8633-
1264  
83 47% seq Minor 4/21 7/16 3/20 25/25 0/1 
∆22 r.8755_8953del199 92 70% seq Minor 28/33 16/16 11/20 9/22 0/1 
∆22,23p r.8755_9004del250 86 63% seq Minor 27/33 15/16 3/18 9/19 not tested 
∆23p r.8954_9004del51 87 14% inferred Minor 0/36 5/16 5/14 7/21 not tested 
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Table 2 
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BRCA2 
splice 
variant 
HGVS nomenclature biotype 
fuctional 
annotation 
CDS 
Functional 
domains/biological 
activities predicted to 
be targeted ** 
LCL 
detection 
MCF7 
HCC
1937 
BT
20 
MCF
10A 
184
A1 
184
B5 
% 
positive 
cell lines 
in phase 
II 
Previously 
reported 
in 
literature 
*** 
∆2 r.-38_67del106 cassette non coding 
 
9/11 + + + + + – 82% no 
∆3 r.68_316del249 cassette no FS p.Asp23_Leu105del PALB2 binding. EMSY 
binding. 
Transcriptional 
Activation 
10/10 + + + + + + 100% yes 
∆3,4 r.68_c.425del359 multi-cassette PTC-NMD 
 
11/11 – + + – + 
– 
82% no 
∆3−7 r.68_631del564 multi-cassette no FS p.Asp23_Ile210del PALB2 binding. EMSY 
binding. 
Transcriptional 
Activation 
9/11 + + + + + + 88% no 
∆4 r.317_425del109 cassette PTC-NMD 
 
8/11 – + + – – – 59% no 
∆4−7 r.317_631del315 multi-cassette no FS p.Gly106_Ile210del CEP55-TSG111 
binding CEP55-Alix 
binding 
11/11 + + + – + – 88% no 
∆5 r.426_475del50 cassette PTC-NMD 
 
11/11 + + + – + + 94% yes 
∆5,6 r.426_516del91 cassette PTC-NMD 
 
7/10 – + + – + – 62% yes 
∆5−7 r.426_631del206 multi-cassette PTC-NMD 
 
10/11 – + + + + + 88% no 
∆6 r.476_516del41 cassette PTC-NMD 
 
4/10 + + + – + – 50% yes 
▼5p† r.426-23_426-1ins 23 cassette PTC-NMD 
 
5/10 – – + + + – 50% no 
∆6q,7 r.478-631del154 splice donor 
shift+cassette 
PTC-NMD 
 
7/10 + + + + + + 81% no 
∆9−11†† r.682_6841del6160 multi-cassette PTC-NMD 
 
2/11 – – + – + – 29% no 
∆12∗§ r.6842_6937del96 cassette no FS p.Glu2282_Gly2313
del 
None**** 6/12 + + + + + + 67% yes 
∆12,13 r.6842_7007del166 multi-cassette PTC-NMD 
 
6/11 + + + – + + 65% no 
∆17§ r.7806_7976del171 cassette no FS p.Ala2603_Arg2659
del 
DNA binding. DSS1 
binding 
9/10 – – + – + – 69% no 
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∆17,18 r.7806_8331del526 multi-cassette PTC-NMD 
 
9/10 + + + + + – 88% yes 
∆18 r.7977_8331del355 cassette PTC-NMD 
 
9/11 + + + + + – 82% yes 
∆19 r.8332_8487del156 cassette PTC-NMD 
 
9/10 + + + + + + 94% no 
∆20 r.8488_8632del145 cassette PTC-NMD 
 
8/11 – – – – + – 53% no 
▼20A §§ r.8633-1327_8633-
1264ins64 
cassette PTC-NMD 
 
7/11 + + + + + + 76% no 
∆22 r.8755_8953del199 cassette PTC-NMD 
 
10/11 – + – – + – 70% no 
∆22,23p r.8755_9004del250 cassette+splice 
acceptor shift 
PTC-NMD 
 
4/10 – + + – + + 50% no 
∆23p  r.8954_9004del51 splice acceptor shift PTC-NMD 
 
3/10 + + + + + + 56% no 
 
 
 
▼20Α,∆22  r.8633-1327_8633-
1264ins64+8755_8953del199 
multi-cassette PTC-NMD 
          
▼20Α,∆22,23  r.8633-1327_8633-
1264ins64+8755_9117del363 
multi-cassette PTC-NMD 
          
∆11 r.1910_6841del4932 cassette no FS p.Leu638_Val2280del Rad51 binding.   
DNA recombination. 
   
∆11,12 r.1910_6937del5028 multi-cassette no FS p.Leu638_Gly2313del Rad51 binding.   
DNA recombination. 
   
∆11−13 r.1910_7008del5099 multi-cassette PTC-NMD 
          
 
* An additional LCL was tested for the ∆12 alternate splicing event. 
** Predictions have been made based on the following BRCA2 protein domain definitions[49]: 
binding to PALB2 and EMSY (residues 10-40), transcriptional activity (residues 24-105), binding to 
CEP55-TSG111 and CEP55-Alix (residues 200-600), Rad 51 binding (residues 638-2280), DNA and 
DSS1 binding domain (residues 2459-3190).   
*** References are listed in the table legend. 
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**** Exon 12 has been reported to be functionally redundant [40] 
† Predicted from a previous mutation analysis (see text)  
 †† Identified in ENCODE 
 § Genescan prediction/H-Inv 7.0 GenePrediction 
 §§ Ensenble transcript ENST00000528762 
Alternate splice variants in italics were identified after this work was completed and were not part of this 
study (see text).
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Table 3 
 
BRCA2 alternate 
splicing events 
reported to be 
asociated with a 
sequence variant 
Sequence variant Reference 
∆2 c.67+2T>C Martinez-Ferrandis et al. 2003 Hum Mutat 22:417 
∆2 c.67+1G>A Bonatti et al. 2006 Cancer Genet Cytogenet 170:93 
∆2 c.67+3A>G Parsons et al. 2013 Mol Carcinog (Epub) doi: 10.1002/mc.22116. 
∆3 c.316+5G>A Thomassen et al. 2012 Br Ca Res Trt 132:1009 
∆3 c.316+5G>C Bonnet et al. 2008 J Med Genet 45:438 
∆3 c.68-7T>A Sanz et al. 2010 Clin Cancer Res 16:1957 
∆3 c.145G>T Sanz et al. 2010 Clin Cancer Res 16:1957 
∆3 c.93G>T Sanz et al. 2010 Clin Cancer Res 16:1957 
∆3 c.156_157insAlu Machado et al. 2007 J Clin Oncol 25:2027 
∆3 c.231T>G Thery et al. 2011 Eur J Hum Genet 19:1052 
∆3 c.68–7delT Santarosa et al. 1999 Genes Chromosomes Cancer 26:381 
∆3,4 c.68-7T>A Santos et al. 2014 J Mol Diag 16:324 
∆3−7 none reported Not applicable 
∆4 c.425G>T Brandão et al. 2011 Br Ca Res Treat 129:971 
∆4−7 none reported Not applicable 
∆5 c.426-12_426-8del Zhang et al. 2009 Mut Res 663:84;  Whiley et al. 2011 Hum Mutat 32:678 
∆5 c.439C>T Sanz et al. 2010 Cancer Res 16:1957 
∆5 c.475+1G>A Colombo et al. 2013 PLoS ONE 8(2): e57173 
∆5 c.516+1G>A Claes et al. 2003 Genes C'somes Can 37:314  
∆5 c.455C>A Sanz et al. 2010 Clin Cancer Res 16:1957 
∆5 c.470_474del Sanz et al. 2010 Clin Cancer Res 16:1957 
∆5 c.473C>T Sanz et al. 2010 Clin Cancer Res 16:1957 
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∆5,6 c.476-2A>G Colombo et al. 2013 PLoS ONE 8(2): e57173 
∆5,6 c.516G>A Hansen et al. 2010 Br Ca Res Treat 119:547 
∆5,6 c.516+1G>A Claes et al. 2003 Genes C'somes Can 37:314 
∆5,6 c.516+1G>T Whiley et al. 2011 Hum Mutat 32:678 
∆5−7 none reported Not applicable 
▼5p none reported Not applicable 
∆6 c.516G>A Hansen et al. 2010 Br Ca Res Treat 119:547 
∆6 c.516+1G>A Claes et al. 2003 Genes C'somes Can 37:314 
∆6 c.516+1G>T Whiley et al. 2011 Hum Mutat 32:678 
∆6 c.476-2A>G Machackova et al. 2008, BMC Cancer 8:140; Colombo et al. 2013 PLoS ONE 8(2): 
e57173 
∆6q,7 none reported Not applicable 
∆9−11 none reported Not applicable 
∆12 c.6853A>G  Li et al. 2009 Hum Mutat 30:1543 
∆12 c.7007G>A Machackova et al. 2008 BMC Cancer 8:140 
∆12,13 c.7007G>A Machackova et al. 2008 BMC Cancer 8:140;  Houdayer et al. 2012 Hum Mutat 
33:1228 
∆12,13 c.7007G>C Houdayer et al. 2012 Hum Mutat 33:1228 
∆12,13 c.5987C>G Caux-Moncoutier et al. 2009 Eur J Hum Genet 17:1471 
∆17 c.7976G>C Farrugia et al. 2008  Cancer Res 68:3523 
∆17 c.7976+3_7974+4del Brandão et al. 2011 Br Ca Res Treat 129:971 
∆17 c.7976G>A Farrugia et al. 2008 Cancer Res 68:3523; Hofmann et al. 2003 J Med Genet 40:e23 
∆17 c.7975A>G Houdayer et al. 2012 Hum Mutat 33:1228 
∆17 c.7806-9T>G Kwong et al. 2008 Fam Cancer 7:125 
∆17 c.7806-2A>G Santarosa et al. 1999 Int J Cancer 83:5 
∆17,18 c.7977-1G>C Tesoriero et al. 2005 Hum Mut #850 Online 
∆17,18 c.7988A>T Walker et al. 2010 Hum Mut 6:E1484 
∆17,18 c.8257_8259del Bonnet et al. 2008 J Med Genet 45:438 
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∆18 c.7977-1G>C Tesoriero et al. 2005 Hum Mut #850 Online 
∆18 c.7988A>T Farrugia et al. Cancer Res 2008 68:3523;  Walker et al. 2010 Hum Mut 6:E1484 
∆18 c.8257_8259del Bonnet et al. 2008 J Med Genet 45:438 
∆18 c.8331+6G>T Goina et al. 2008 Mol Cell Biol 28:3850 
∆18 c.8165C>G Fackenthal et al. 2002 Am J Hum Genet 71:625 
∆18 c.8331G>A Sanz et al. 2010 Clin Cancer Res 16:1957 
∆18 c.7977-7C>G Houdayer et al. 2012 Hum Mutat 33:1228 
∆19 c.8487+1G>A Chen et al. 2006 Hum Mut 27:427; Agata et al. 2003 Can Genet Cytogenet 
141:175; Acedo et al et al. 2012 Br Can Res Treat 14:R87  
∆19 c.8378G>A Acedo et al et al. 2012 Br Can Res Treat 14:R87 
∆19 c.8486A>T Acedo et al et al. 2012 Br Can Res Treat 14:R87 
∆19 c.8487G>A Acedo et al et al. 2012 Br Can Res Treat 14:R87 
∆19 c.8487+3A>G Acedo et al et al. 2012 Br Can Res Treat 14:R87 
∆19 c.8486A>G Houdayer et al. 2012 Hum Mutat 33:1228; Chenevix-Trench et al. 2006 Cancer Res 
66:2019 
∆19 c.8487G>C Houdayer et al. 2012 Hum Mutat 33:1228 
∆20 c.8488-2A>G Acedo et al et al. 2012 Br Can Res Treat 14:R87 
∆20 c.8488-1G>A Acedo et al et al. 2012 Br Can Res Treat 14:R87 
∆20 c.8632+1G>A Tesoriero et al. 2005 Hum Mut #850 Online 
▼20A  none reported Not applicable 
∆22 c.8755-1G>A Machackova et al. 2008 BMC Cancer 8:140;  Colombo et al. 2013 PLoS ONE 8(2): 
e57173 
∆22,23p c.8755-1G>A Colombo et al. 2013 PLoS ONE 8(2): e57173 
∆23p  c.8954-
1_8955delinsAA 
Acedo et al et al. 2012 Br Can Res Treat 14:R87; Colombo et al. 2013 PLoS ONE 
8(2): e57173 
∆23p  c.8969G>A Acedo et al et al. 2012 Br Can Res Treat 14:R87 
∆23p  c.9006A>T Acedo et al et al. 2012 Br Can Res Treat 14:R87 
∆23p  c.9117G>A Acedo et al et al. 2012 Br Can Res Treat 14:R87 
Page 52 of 62
https://mc.manuscriptcentral.com/jmedgenet
Journal of Medical Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 43
 
Table S1a 
Experiments performed by: 
 
INT, Milano INT, Milano HVH, Barcelone HVH, Barcelone HVH, Barcelone HCSC, Madrid 
Samples provided by: 
 
INT, Milano INT, Milano and 
QIMR, Brisbane 
HVH, Barcelone  QIMR, Brisbane HVH, Barcelone HCSC, Madrid 
Samples (detection method): PBLs (capillary 
EP) 
LCLs (capillary 
EP) 
LEUs (agarose) LCLs (agarose) PBMCs (agarose) LEUs (capillary 
EP) 
 
Splicing event mRNA position  
      
 
∆2 r.38_67del106 0/1 0/6 not tested not tested not tested 0/13 
 
∆3 r.68_316del249 1/1 6/6 18/18 10/10 8/8 13/13 
 
∆3,4 r.68_c.425del359 0/1 5/6 0/18 0/10 0/8 13/13 
 
∆3−7 r.68_631del564 0/1 5/6 not tested not tested not tested not tested 
 
∆4 r.317_425del109 0/1 0/6 0/18 0/10 0/8 0/13 
 
∆4−7 r.317_631del315 0/1 6/6 not tested not tested not tested 5/20 
 
∆5 r.426_475del50 0/1 0/6 0/19 0/10 0/8 2/20 
 
∆5,6 r.426_516del91 0/1 1/6 0/19 0/10 0/8 2/13 
 
∆5−7 r.426_631del206 0/1 5/6 0/19 0/10 0/8 3/20 
 
∆6 r.476_516del41 0/1 0/6 0/19 0/10 0/8 17/20 
 
∆6q,7 r.478-631del154 1/1 6/6 19/19 10/10 8/8 20/20 
 
∆12 r.6842_6937del96 1/1 4/4 not tested not tested not tested 5/8 
 
∆12,13 r.6842_7007del166 0/1 0/4 not tested not tested not tested 1/13 
 
∆17 r.7806_7976del171 not tested not tested 0/21 0/10 0/8 0/13 
 
∆17,18 r.7806_8331del526 2/2 3/3 21/21 10/10 8/8 23/23 
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∆18 r.7977_8331del355 2/2 3/3 21/21 10/10 8/8 19/28 
 
∆19 r.8332_8487del156 not tested 9/9 0/21 0/10 0/8 1/13 
 
∆20 r.8488_8632del145 1/2 1/3 0/16 0/10 0/8 2/3 
 
▼20A c.8633-1327_c.8633-1264ins64 2/2 3/3 0/16 10/10 0/8 4/5 
 
∆22 c.8755_8953del199 0/2 0/3 23/23 0/10 8/8 5/10 
 
∆22,23p c.8755_9004del250 not tested not tested 23/23 0/10 8/8 4/10 
 
∆23p c.8954_9004del51 0/2 0/3 0/23 0/10 0/8 0/13 
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Table S1b 
HCSC, Madrid  HCSC, Madrid HCSC, Madrid HCSC, Madrid HCSC, Madrid  MU, Maastrich QIMR, Brisbane Cologne University Southampton General 
Hospital 
HVH, Barcelone USC, Santiago de 
Compostela 
 MU, Maastrich QIMR, Brisbane HCSC, Madrid  MU, Maastrich QIMR, Brisbane Cologne University Southampton General 
Hospital 
PBMCs (capillary 
EP) 
PBLs (capillary 
EP) 
PBLs (capillary 
EP) 
LCLs  (capillary 
EP) 
One healthy 
breast tissue 
(capillary EP) 
PBLs (agarose) LCLs  (agarose) LCLs (agarose) LEU detected/tested 
(agarose) 
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0/8 9/16 not tested 6/10 0/1 2/2 0/4 not tested not tested 
8/8 14/16 not tested 10/10 1/1 2/2 3/4 2/2 3/3 
8/8 7/16 not tested 10/10 0/1 not tested 0/4 not tested not tested 
5/8 2/6 not tested 7/9 not tested not tested not tested not tested not tested 
3/8 2/16 not tested 10/10 0/1 not tested 0/4 not tested not tested 
7/8 6/6 not tested 9/10 0/1 not tested not tested not tested not tested 
4/8 4/6 not tested 10/10 1/1 not tested not tested not tested not tested 
0/8 0/6 not tested 0/10 0/1 not tested 0/15 not tested not tested 
8/8 5/6 not tested 10/10 1/1 not tested 0/15 not tested not tested 
0/8 0/6 not tested 0/10 1/1 not tested 0/15 not tested not tested 
8/8 6/6 not tested 10/10 1/1 4/4 15/15 not tested not tested 
5/8 6/6 not tested not tested 1/1 3/3 not tested 2/2 3/3 
0/8 0/6 not tested not tested 0/1 not tested not tested not tested not tested 
0/8 0/12 0/12 7/10 1/1 not tested not tested not tested not tested 
8/8 12/12 12/12 10/10 1/1 not tested 15/15 not tested not tested 
8/8 12/12 11/12 10/10 1/1 not tested 15/15 not tested 3/3 
5/8 3/10 6/12 9/10 not tested not tested not tested not tested not tested 
2/8 2/6 0/12 7/10 1/1 not tested not tested not tested not tested 
7/8 5/6 3/12 10/10 0/1 1/1 not tested 2/2 not tested 
8/8 3/6 8/12 9/9 0/1 not tested not tested not tested not tested 
7/8 1/6 2/12 9/9 not tested not tested not tested not tested not tested 
5/8 5/6 0/6 7/8 not tested not tested not tested not tested 
not tested 
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Table S2 
 
Alternate splicing 
event to be detected 
Forward or 
reverse 
Primer name and sequence 
∆2 F (full length) BR2ex1-2F: AGAACTGCACCTCTGGAGCGGACTTATTT  
 F (alternate) BR2ex1-3F: AGAACTGCACCTCTGGAGCGGATTTAGGA 
 R  BR2CA2 Ex 7R: CTAAAGAACTTGACCAAGAC 
   
∆3 F (full length) BRCA2 EX2-3F(a): ACACGCTGCAACAAAGCAGATT  
 F (alternate) BRCA2 EX2-4F: ACACGCTGCAACAAAGCAGGAA 
 R BRCA2 Ex 7R: CTAAAGAACTTGACCAAGAC 
   
∆3,4 F (full length) BRCA2ex2-3F(b): TTTTAAGACACGCTGCAACAAAGCAGATTTA  
 F (alternate) BRCA2ex2-5F: TTTTAAGACACGCTGCAACAAAGCAGTCCTG 
    R BRCA2 Ex8-7R: CTTCATTTCTGACTATGAGC 
   
∆3-7 F (full length) BR2ex2-3F(c): AAGACACGCTGCAACAAAGCAGATT  
 F (alternate) BR2ex2-8F: AAGACACGCTGCAACAAAGCAGTCA  
 R  BRCA2 Ex 10R: GATCAGTATCATTTGGTTCC 
   
∆4 F (full length) BRCA2ex3-4F(a): ATAAATTCAAATTAGACTTAGGAAG 
 F (alternate) BRCA2ex3-5F: ATAAATTCAAATTAGACTTAGTCCT 
 R BRCA2 Ex8-7R: CTTCATTTCTGACTATGAGC 
   
∆4-7 F (full length) BR2ex3-4F(b): GATAAATTCAAATTAGACTTAGGAAGG 
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 F (alternate) BR2ex3-8F: GATAAATTCAAATTAGACTTAGTCAGA 
 R BRCA2 Ex 10R: GATCAGTATCATTTGGTTCC 
   
∆5 F (full length) BRCA2 Ex4-5F(a): CTAAATTCTTGTCTTAGTGAAAGTCCTG 
 F (alternate) BRCA2 Ex4-6F: CTAAATTCTTGTCTTAGTGAAAGTGGTA 
 R BRCA2 Ex8-7R: CTTCATTTCTGACTATGAGC 
   
∆5,6 F (full length) BR2ex4-5F(b): CCACTTCTAAATTCTTGTCTTAGTGAAAGTCCT 
 F (alternate) BR2ex4-7F: CCACTTCTAAATTCTTGTCTTAGTGAAAGGGTC 
 R BRCA2 Ex 10R: GATCAGTATCATTTGGTTCC 
   
∆5-7 F (full length) BRCA2ex4-5F(c): AAATTCTTGTCTTAGTGAAAGTCCTGT 
 F (alternate) BRCA2ex4-8F: AAATTCTTGTCTTAGTGAAAGTCAGAA 
 R BRCA2 Ex 10R: GATCAGTATCATTTGGTTCC 
   
▼5p F (full length) BR2ex4-5F(b): CCACTTCTAAATTCTTGTCTTAGTGAAAGTCCT 
 F (alternate) BR2ex5+23F: CTAAATTCTTGTCTTAGTGAAAGGGA  
 R BRCA2 Ex8-7R: CTTCATTTCTGACTATGAGC 
   
∆6 F (full length) BRCA2ex5-6F(a): CACCACAAAGAGATAAGTCAGTGGTA 
 F (alternate) BRCA2ex5-7F: CACCACAAAGAGATAAGTCAGGGTCG 
 R BRCA2 Ex10R: GATCAGTATCATTTGGTTCC 
   
∆6q7 F (full length) BRCA2 EX 5-6F(b): ACAAAGAGATAAGTCAGTGGTAT 
 F (alternate) BRCA2 EX 5-8+2: ACAAAGAGATAAGTCAGTGTCAG 
 R BRCA2 Ex10R: GATCAGTATCATTTGGTTCC 
   
∆9-11 F (full length) BR2ex8-9F: GTATTTCCTCATGATACTACTGCTAATG* 
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 F (alternate) BR2ex8-12F: GTATTTCCTCATGATACTACTGCTGAGA 
 R BRCA2 Ex 14R: TGCTAAATTGCTTGAAGATT 
   
∆12 F (full length) BR2EX11-12F(a): AGCCCCTTATCTTAGTGGGAGA  
 F (alternate) BR2EX11-13F: AGCCCCTTATCTTAGTGGGCAC  
 R BRCA2 Ex 14R: TGCTAAATTGCTTGAAGATT 
   
∆12,13 F (full length) BR2ex11-12F(b): AAGAAGAGGAGAGCCCCTTATCTTAGTGGGAG  
 F (alternate) BR2ex11-14F: AAGAAGAGGAGAGCCCCTTATCTTAGTGGCAC  
 R BRCA2 Ex14R: TGCTAAATTGCTTGAAGATT 
   
∆17 F (full length) BR2ex 16-17F(a):  GGAAAAGAAGAATTTTATAGGGC 
 F (alternate) BR2ex 16-18F:  GGAAAAGAAGAATTTTATAGATA 
 R BRCA2 Ex18R: TTTCAGATATATTTGCGCTC 
   
∆17-18 F (full length) BR2ex16-17F(b): GGAAAGGCTGGAAAAGAAGAATTTTATAGGGC  
 F (alternate) BR2ex16-19F: GGAAAGGCTGGAAAAGAAGAATTTTATAGATT 
 R BRCA2ex22R: AACATTTGCCTGTGATTATT 
   
∆18 F (full length) BR2ex17-18F: GCTTCTTCAACTAAAATACAGATATGA 
 F (alternate) BR2ex17-19F: GCTTCTTCAACTAAAATACAGATTTCT 
 R BRCA2 Ex23R: TGTATGTTAGCTCTTTCAGA 
   
∆ 19 F (full length) BR2ex 18-19F: GAATCTCTTATGTTAAAGATT 
 F (alternate) BR2ex 18-20F: GAATCTCTTATGTTAAAGTGG 
 R BRCA2 Ex23R: TGTATGTTAGCTCTTTCAGA 
   
∆20 F (full length) BR2ex19-20F: ATTATTCAAAGAGCATACCCTATACAGTGG 
Page 59 of 62
https://mc.manuscriptcentral.com/jmedgenet
Journal of Medical Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 50
 F (alternate) BR2ex19-21F: ATTATTCAAAGAGCATACCCTATACAGAAA 
 R BRCA2 Ex23R:TGTATGTTAGCTCTTTCAGA 
   
▼20A  F (full length) BRCA2ex20-21F: GGAATTTGAAGAACATGAAGAAAAC  
 F (alternate) BRCA2ex20-i20F: GGAATTTGAAGAACATGAAGTTACT 
 R BRCA2 EX22R: AACATTTGCCTGTGATTATT 
   
∆22 F (full length) BRCA2ex21-22F(a): CAGACCCAGCTTACCTTGAGGGT 
 F (alternate) BRCA2ex21-23F: CAGACCCAGCTTACCTTGAGTTATA 
 R BRCA2 Ex23R: TGTATGTTAGCTCTTTCAGA 
   
∆22,23p F (full length) BR2ex21-22(b): GACCCAGCTTACCTTGAGGGT 
 F (alternate) BR2ex21-delex23p: GACCCAGCTTACCTTGAGAAG 
 R BRCA2 Ex23R: TGTATGTTAGCTCTTTCAGA 
   
∆23p F (full length) BR2ex 22-23F: GCTATTCAAAAAAAGAAAAAGATTCAGTTA 
 F (alternate) BR2ex22-delex23pF: GCTATTCAAAAAAAGAAAAAGATTCAGAAG 
 R BRCA2 Ex23R: TGTATGTTAGCTCTTTCAGA 
   
   
*Note: this may not always be a practical positive control as the predicted RT-PCR product is 6.5 kb. 
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Supplementary Materials and Methods 
 
 
BRCA2 alternate splicing event nomenclature: 
The naming of BRCA2 alternate splicing events in this study follows the 
conve tion used by Colombo et al. [6].   Briefly, the exon number preceded by the 
letter delta (∆) indicate alternate splicing events resulting from single exon 
skipping.  Commas or dashes indicate events resulting in skipping of two or more 
contiguous exons, respectively.  Events involving a shifted splice donor (distal) or 
splice acceptor (proximal) are indicated with p or q, respectively.  The alternate 
splice acceptor within intron 4 that adds 23 bases to the 5’ end of exon 5 is indicated 
by the event designation ▼5p.  Exonization of a region of intron 20 is indicated by 
the designation ▼20A.  Corresponding HGVS nomenclature for the alternate splicing 
events is according to the Human Genome Variation Society nomenclature 
guidelines (http://www.hgvs.org/rechtml).  
 
Identification of alternate BRCA2 splicing events in the literature: 
We define naturally occurring alternative splicing events as those resulting 
from alternate splice site choices during regular mRNA processing and are not 
caused by RNA sequence variants.   
 
To determine which alternate BRCA2 mRNA splicing events have been 
described previously, a PubMed search was performed 
(http://www.ncbi.nlm.nih.gov/pubmed) using search terms BRCA2, alternate 
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splicing, and mRNA.  For the purpose of this study, the results were reviewed to 
determine whether the cDNA fragment representing the alternate splicing event had 
been sequenced and whether the event occurred independently of a variation in the 
gene sequence.  
 
Patient samples and cell lines:  
In phase II, lymphoblastoid cell lines were taken from archival stocks of 
samples from eleven breast cancer patients who were consented under a protocol 
approved by the University of Chicago Institutional Review Board.  All patients were 
referred for BRCA1/BRCA2 genetic testing by the University of Chicago Cancer Risk 
Clinic for reasons of personal or family history of cancer.  Nine subjects were 
diagnosed with breast cancer, one with fallopian tube cancer, and one with no 
cancer diagnosis.  Of the eleven subjects used for all alternate splicing events, four 
had no detected gene sequence variants, one had a pathogenic variant in BRCA1, and 
one had a pathogenic variant in PALB2.  The remaining five carried BRCA2 
truncating variants: three were in exon 11 at positions not predicted to affect exon 
11 splicing (c.5864C>A (p.Ser1955*), c.2808_2811del , c.5350_5351del;), one was in 
exon 4 (c.391delT), and another in exon 18 (c.8297delC).  We note that exon 
skipping events involving exon 4, either alone or in combination with other exons, 
were detected in the majority of cell lines tested, not just the cell line with the exon 
4 pathogenic variant.  Likewise, the exon skipping events involving exon 18 were 
seen in the majority of cell lines tested.  We therefore suggest that these mutations 
did not affect the identification of naturally occurring exon-skipping events 
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described below.  Breast cancer cell lines were MCF7 (from an ER+ invasive ductal 
carcinoma with a luminal epithelial phenotype), HCC1937 (from a ductal carcinoma 
carrying a homozygous pathogenic variant in BRCA1), and BT20 (from a triple-
negative invasive ductal carcinoma).  None of these cell lines has any known 
mutation in BRCA2.  Non-cancer breast cell lines were MCF10A (derived from 
mammary epithelial cells associated with fibrocystic disease), 184A1 (from 
chemically transformed breast epithelial cells), and 184B5 (a different isolate from 
the procedure that generated 184A1) [50].  Breast cell lines were obtained from the 
American Tissue Type Collection (ATTC).  Cell lines were grown with conventional 
media and conditions.  Multiple LCLs and breast cell lines (see above) were used to 
test the detectability of alternate splicing events identified in phases Ia and Ib.  No 
attempt was made to provide definitive characterization of any single cell type with 
respect to specific alternate splicing events in Phase II.  Thus, in most cases, each cell 
line was tested once per alternate splicing event (Table 2).   
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